首页> 美国卫生研究院文献>Oncotarget >A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209

【2h】

A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209

机译：培那洛普和多西他赛或多西他赛单独用于转移性去势抵抗性前列腺癌的男性的随机II期研究：CCTG研究IND 209

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundPelareorep is an oncolytic virus with activity in many cancers including prostate. It has in vitro synergism with microtubule-targeted agents. We undertook a clinical trial evaluating pelareorep in mCRPC patients receiving docetaxel.

机译：背景Pelareorep是一种溶瘤病毒，在包括前列腺在内的许多癌症中均具有活性。它与微管靶向药物具有体外协同作用。我们进行了一项临床试验，评估接受多西他赛的mCRPC患者中的pelareorep。

著录项

期刊名称 Oncotarget
作者
Bernhard Josef Eigl; Kim Chi; Dongsheng Tu; Sebastien J. Hotte; Eric Winquist; Christopher M. Booth; Christina Canil; Kylea Potvin; Richard Gregg; Scott North; Muhammad Zulfiqar; Susan Ellard; Joseph Dean Ruether; Lyly Le; A. Saranya Kakumanu; Mohammad Salim; Alison L. Allan; Harriet Feilotter; Ashley Theis; Lesley Seymour;
展开▼
作者单位

展开▼
年(卷),期 2018(9),8
年度 2018
页码 8155–8164
总页数 10
原文格式 PDF
正文语种
中图分类肿瘤学;细胞生物学;
关键词
prostate cancer oncolytic viruses chemotherapy clinical trial;

机译：前列腺癌;溶瘤病毒;化学疗法;临床试验;

相似文献

外文文献
中文文献
专利

1. Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer [J] . DeBonoJ.S., PiulatsJ.M., PandhaH.S., Clinical cancer research: an official journal of the American Association for Cancer Research . 2014,第7期

机译：非格非单抗联合多西他赛和多西他赛单独与交叉治疗转移性去势抵抗性前列腺癌的II期随机研究
2. 7004 Final results of a randomized phase II study of OGX-011 (OGX) in combination with docetaxel (DOC)/prednisone versus docetaxel/prednisone in patients with metastatic castration resistant prostate cancer (CRPC) [J] . K.N.Chi, S.J.Hotte, E.Yu, European Journal of Cancer Supplements . 2009,第2期

机译：7004 OGX-011（OGX）联合多西他赛（DOC）/泼尼松与多西他赛/泼尼松对转移性去势抵抗性前列腺癌（CRPC）患者的随机II期研究的最终结果
3. A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial [J] . van Dodewaard-de Jong Joyce M., de Klerk John M. H., Bloemendal Haiko J., European Journal of Nuclear Medicine and Molecular Imaging . 2017,第8期

机译：对重复的铼-188-HEDP的随机的II类研究与多西紫杉醇和泼尼松与多西紫杉醇和泼尼松相结合，仅在抗阉割的前列腺癌（CRPC）转移到骨中; 税款II审判
4. Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer: A Decade of Progress and Ongoing Discoveries [C] . Leonel Hernez-Aya, Maha Hussain Genitourinary Cancers Symposium. . 2014

机译：转移激素敏感和阉割的前列腺癌：进步和持续发现的十年
5. Optimization of Survivin Dimerization Inhibitors for the Treatment of Docetaxel-Resistant Prostate Cancer [D] . Peery, Robert Craig. 2020

机译：Survivin二聚化抑制剂的优化治疗多西紫杉醇抗性前列腺癌
6. Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer [O] . Judith Passildas‐Jahanmohan, Jean‐Christophe Eymard, Mélanie Pouget, 2021

机译：多中心随机期II研究比较Docetaxel Plus姜黄素与Docetaxel Plus安慰剂在第一线治疗转移阉割前列腺癌中
7. Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study) [O] . O. Caffo, E. Palesandro, F. Nole, 2019

机译：更新的多中心期II型随机试验的多元丙二酸（D）加苯甲酰胺（e）与多元紫杉醇（d）作为患者（PTS）的多元化化疗，具有转移性阉割的前列腺癌（MCRPC）（Cheiron研究）

A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209

摘要

著录项

相似文献

相关主题

期刊订阅